Why the study?
Are angiotensin II receptor antagonists as effective as ACE inhibitors with a better side-effect profile in patients with hypertension, heart failure, and chronic renal disease?
Are angiotensin II receptor antagonists as effective as ACE inhibitors with a better side-effect profile in patients with hypertension, heart failure, and chronic renal disease?
Answers are grounded in this paper and cite their sources.
Angiotensin II receptor antagonists are effective alternatives to ACE inhibitors for hypertension, heart failure, and chronic renal disease, offering an improved side-effect profile without persistent dry cough.
The non-peptide angiotensin II (AII) receptor antagonists are a new class of compounds that are continuing to be developed as therapeutic agents for the treatment of hypertension, heart failure (HF) and chronic renal disease (CRD). Several of these compounds are currently available for therapeutic use in the USA and the European community with several more in clinical trials and in development. Compounds in this new class are as effective as angiotensin converting enzyme (ACE) inhibitors in treating hypertensive patients and appeared to have a similar therapeutic profile to ACE inhibitors in patients with HF and CRD. One clinical advantage of the AII receptor antagonists over ACE inhibitors is an improved side-effect profile with the absence of the persistent dry cough associated with ACE inhibitor therapy. To date, it is clear that the AII receptor antagonists are effective antihypertensive agents. Clinical trials are currently in progress to determine the therapeutic efficacy of these drugs in the treatment of HF and progressive renal disease.
No takes yet. Share an insight, caveat, or question.
David J. Dzielak (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: